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Abstract
Background—Co-morbidity with tuberculosis and HIV is a common cause of mortality in sub-
Saharan Africa. In the second Kenya AIDS Indicator Survey, we collected data on knowledge and 
experience of HIV and tuberculosis, as well as on access to and coverage of relevant treatment 
services and antiretroviral therapy (ART) in Kenya.
Methods—A national, population-based household survey was conducted from October 2012 to 
February 2013. Information was collected through household questionnaires, and blood samples 
were taken for HIV, CD4 cell counts, and HIV viral load testing at a central laboratory.
Results—Overall, 13,720 persons aged 15–64 years participated; 96.7% [95% confidence 
interval (CI): 96.3 to 97.1] had heard of tuberculosis, of whom 2.0% (95% CI: 1.7 to 2.2) reported 
having prior tuberculosis. Among those with laboratory-confirmed HIV infection, 11.6% (95% CI: 
8.9 to 14.3) reported prior tuberculosis. The prevalence of laboratory-confirmed HIV infection in 
persons reporting prior tuberculosis was 33.2% (95% CI: 26.2 to 40.2) compared to 5.1% (95% 
CI: 4.5 to 5.8) in persons without prior tuberculosis. Among those in care, coverage of ART for 
treatment-eligible persons was 100% for those with prior tuberculosis and 88.6% (95% CI: 81.6 to 
95.7) for those without. Among all HIV-infected persons, ART coverage among treatment-eligible 
persons was 86.9% (95% CI: 74.2 to 99.5) for persons with prior tuberculosis and 58.3% (95% CI: 
47.6 to 69.0) for those without.
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Conclusions—Morbidity from tuberculosis and HIV remain major health challenges in Kenya. 
Tuberculosis is an important entry point for HIV diagnosis and treatment. Lack of knowledge of 
HIV serostatus is an obstacle to access to HIV services and timely ART for prevention of HIV 
transmission and HIV-associated disease, including tuberculosis.
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INTRODUCTION
Tuberculosis is the leading cause of death in persons with HIV.1 Co-morbidity from HIV 
and tuberculosis remains an important public health challenge worldwide but 
disproportionately affects sub-Saharan Africa. The Word Health Organization (WHO) 
reported that a total of 8.7 million cases of tuberculosis occurred globally in 2011, with 24% 
in the African region.2 About 13% of tuberculosis cases worldwide were co-infected with 
HIV, and approximately 430,000 deaths in HIV-infected persons in 2011 were due to 
tuberculosis.2 Because HIV infection rates are highest in sub-Saharan Africa, infection with 
tuberculosis is highly prevalent there, and people living with HIV are at increased risk for 
developing tuberculosis disease, sub-Saharan Africa is especially affected by comorbidity 
from HIV and tuberculosis.3 In 2011, sub-Saharan Africa accounted for 79% of all cases of 
HIV-associated tuberculosis in the world, and 39% of persons with tuberculosis in the 
region were estimated to be infected with HIV.2
WHO guidelines use tuberculosis as an indicator in the staging of HIV disease, and 
treatment guidelines now recommend antiretroviral therapy (ART) for all HIV-infected 
individuals early after tuberculosis diagnosis.4 To reduce the burden of both diseases and to 
maximize program effectiveness and efficiency, WHO has stressed the importance of strong 
collaboration between tuberculosis and HIV programs and integration of service delivery to 
the extent possible for maximal patient convenience.4,5 Key interventions include HIV 
testing and counseling in tuberculosis clinics, offering HIV prevention services to 
tuberculosis patients, tuberculosis screening and infection control in HIV clinics, provision 
of cotrimoxazole to HIV-infected tuberculosis patients, providing ART to patients with 
HIV-associated tuberculosis early after diagnosis, and offering preventive therapy for 
tuberculosis after exclusion of active disease to all persons living with HIV.
Kenya ranks 13 of 22 countries with high tuberculosis burden.2 Based on the first Kenya 
AIDS Indicator Survey (KAIS 2007), the population prevalence of HIV infection was 7.1% 
among adults and adolescents aged 15–64 years,6 indicating that Kenya ranked fourth in the 
world in numbers of people living with HIV. The HIV prevalence in tuberculosis patients in 
Kenya in 2011 was 39%.7 Implementation of integrated tuberculosis and HIV services has 
improved progressively with uptake of HIV testing in tuberculosis clinics increasing from 
60% in 2006 to at least 88% in 2009.8
Planning and implementation of the second Kenya AIDS Indicator Survey (KAIS 2012) 
offered the opportunity to collect data on aspects of HIV and tuberculosis at the population 
level and to describe the extent of their association. This article describes population-level 
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knowledge about tuberculosis, demographic and clinical characteristics of persons who 
report prior tuberculosis disease and treatment for prior tuberculosis, rates of co-infection 
with tuberculosis and HIV disease, and care and treatment coverage among HIV-infected 
persons by tuberculosis status. These data should be useful to the Kenya Ministry of Health 




The Kenya Medical Research Institute (KEMRI) Ethical Review Committee, the US Centers 
for Disease Control and Prevention (CDC) Institutional Review Board, and the Committee 
on Human Research of the University of California, San Francisco (UCSF), provided ethical 
review and approval of the survey protocol.
Study Design
KAIS 2012 was a nationally representative, population-based, cross-sectional household 
survey of Kenyans aged 18 months to 64 years conducted from October 2012 to February 
2013. This survey, described in detail elsewhere, was the second of its kind in Kenya 
following the first KAIS conducted in 2007.9 It was designed to provide comprehensive data 
on demographic, behavioral, and biologic characteristics of persons living with HIV, in 
addition to providing national HIV prevalence estimates and measurement of HIV/AIDS 
service uptake and need. A household questionnaire was administered to the head of the 
household to collect household-level information. Sex-specific individual questionnaires 
were administered for men and women aged 15–64 years.
Information collected included demographic characteristics, sexual and reproductive history, 
HIV knowledge and attitudes, HIV status and treatment, tuberculosis knowledge, history of 
tuberculosis disease and treatment, and access to tuberculosis clinic services. Blood was 
collected for HIV testing at a central laboratory with identifying information removed from 
specimens. Persons wishing to know their HIV status were offered home-based HIV testing 
and counseling, with point-of-care CD4 cell count measurement and medical referral 
proposed for those found to be HIV-positive.
Study Subjects
This analysis is restricted to persons aged 15–64 years. Individuals who were usual residents 
of the household or spent the night preceding the survey visit in the sampled household were 
considered eligible for participation. Informed verbal consent was obtained from adults aged 
18 years and above or emancipated minors who were pregnant, married, or a parent. Minors 
aged 15–17 years were asked to provide verbal assent, and their parents or guardians were 
asked to provide verbal consent before interviews were conducted.
Laboratory Testing
Biologic testing was performed at the National HIV Reference Laboratory. HIV testing was 
done using Kenya’s validated testing algorithm, which included screening with Vironostika 
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HIV-1/2 UNIF II Plus O Enzyme Immunoassay (bioMérieux, Marcy d’Etoile, France). 
Positive samples were confirmed with the Murex HIV.1.2.O HIV Enzyme Immunoassay 
(DiaSorin, SpA, Saluggia, Italy). Discordant results were retested with the 2 assays. Twice 
discordant results, if they occurred, were tested using a polymerase chain reaction assay 
(Cobas Amplicor HIV-1 Monitor Test, version 1.5; Roche Molecular Diagnostics, 
Pleasanton, CA). For quality control, all positive specimens and 5% of negative specimens 
were retested using the same testing algorithm at the Kenya Medical Research Institute 
laboratory. For persons with positive HIV tests, measurements of CD4 cell counts (BD 
FACSCalibur Flow Cytometer; Becton Dickinson Biosciences, San Jose, CA) were 
performed centrally as well as measurement of HIV viral load (Abbott M2000 Real-Time 
HIV-1 Assay; Abbott Laboratories, Abbott Park, IL).
Data Management and Analysis
Data were collected electronically at the point of interview using tablet computers (Mirus 
Innovations, Mississauga, Ontario, Canada). The data from interview and results of tests 
conducted in the household were electronically transmitted to a central database in Nairobi 
where data cleaning, merging, and weighting were done before analysis.
Tuberculosis disease was defined as self-reported history of tuberculosis diagnosed by a 
doctor or another health professional. Tuberculosis treatment completion was defined by 
self-report of having taken tuberculosis drugs for 6 or 8 months as prescribed by the national 
guidelines on treatment of new or recurrent tuberculosis, respectively. HIV viral suppression 
was defined as HIV RNA concentration <1000 copies per milliliter.
ART coverage was defined as the proportion of treatment-eligible persons who were 
receiving ART. All persons with a history of tuberculosis who were co-infected with HIV 
were considered in need of ART, irrespective of CD4 cell count. For persons infected with 
HIV without a history of tuberculosis, we assumed that those already on ART were 
treatment eligible, irrespective of current CD4 cell count, and they therefore contributed to 
both numerator and denominator for calculation of treatment coverage. In addition, persons 
without prior tuberculosis and not on ART who had a CD4 count ≤350 cells per microliter 
were considered treatment eligible, consistent with national ART guidelines.10
Univariate and bivariate analyses were conducted to quantify associations between various 
demographic and behavioral factors with tuberculosis and HIV co-morbidity. Odds ratios 
(OR), 95% confidence intervals (CI), and P values are presented. Analyses were conducted 
using SAS software version 9.3 (SAS Institute, Inc., Cary, NC). The analysis took into 
account the cluster survey design, and the estimates were weighted to account for the 
probability in sampling and adjusted for nonresponse.
RESULTS
A total of 13,720 persons participated in the survey, of whom 5745 (42.0%) men and 7930 
(58.0%) women answered questions on tuberculosis and were included in this analysis. 
Laboratory diagnoses for HIV infection were available for 11,599 (84.8%) persons.
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Overall, 96.7% reported having ever heard of tuberculosis, with significantly fewer women 
(95.9%) than men (97.7%) having heard of the disease (OR = 0.5; 95% CI: 0.5 to 0.9) 
(Table 1). More than 90% of individuals in all age groups, in all geographic regions, and of 
all educational and wealth levels had heard of tuberculosis. The laboratory-diagnosed 
prevalence of HIV infection in all persons who had heard of tuberculosis was 5.7% (data not 
shown). In contrast, only 2.9% of persons who had heard of tuberculosis reported a previous 
diagnosis of HIV; 28% of persons who had heard of tuberculosis had either never been 
tested for HIV or never received test results.
Of those who had heard of tuberculosis, 85.4% said it is curable, with knowledge slightly 
lower in females than in males (84.3% females vs. 87.0% males; OR = 0.8; 95% CI: 0.7 to 
0.9) (Table 1). Knowledge that tuberculosis is curable was significantly associated with 
educational level; 86.8% of persons with secondary of higher level of education knew it to 
be curable compared with 81.8% of those with no primary education (OR = 1.5; 95% CI: 1.2 
to 1.9). Persons aged 25 years and older were significantly more likely than youth aged 15–
24 years to have correct knowledge (P < 0.001), and there were significant differences in 
knowledge by region, with a range of 90.9% of persons in Nairobi being aware of 
tuberculosis curability to 75.9% in Western region (P < 0.001) and by urban (89.3%) versus 
rural (83.1%) residence (OR = 1.7; 95% CI: 1.4 to 2.0).
Of people who self-reported HIV-positive status, 94.6% knew that tuberculosis is curable, a 
higher proportion than for any other category and significantly higher than for those self-
reporting as HIV-negative (86.7%) (OR = 2.8; 95% CI: 1.7 to 4.6) (Table 1). Persons with 
laboratory-diagnosed HIV infection were also significantly more likely than HIV-negative 
persons to have correct knowledge, although the difference was less marked (89.4% vs. 
85.2%; OR = 1.5; 95% CI: 1.1 to 2.0).
Overall, 46.4% of persons who knew tuberculosis is curable were aware that it can also be 
cured in people living with HIV. This knowledge was significantly associated with self-
reported HIV-positive status; 78.4% persons self-reporting to be HIV-positive were aware 
versus 48.6% among persons self-reporting as HIV-negative (OR = 4.0; 95% CI: 2.8 to 5.7) 
and 39.1% among those who had never been tested or received results (OR = 0.7 compared 
to self-reported HIV-negatives; 95% CI: 0.6 to 0.8) (Table 1). Persons with laboratory-
diagnosed HIV infection were also more likely than those with HIV-negative laboratory 
results to know that tuberculosis is curable in persons living with HIV [67.7% versus 44.7% 
(OR = 2.6; 95% CI: 2.1 to 3.2)]. Age, educational level, wealth index, region, and urban 
versus rural residence were all significantly associated with knowing tuberculosis can be 
cured among HIV-positive persons (P < 0.001). The highest levels of knowledge were in 
Nyanza (55.8%) and Nairobi (56.4%) regions.
History of Tuberculosis and Tuberculosis Treatment
A total of 271 (2.0%) participants who had ever heard of tuberculosis reported ever having 
had tuberculosis (Table 2). Significantly fewer women than men had a history of 
tuberculosis, 1.6% versus 2.4% (OR = 0.7; 95% CI: 0.5 to 0.9). The proportion of persons 
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reporting prior tuberculosis increased with age, from 0.6% in those younger than aged 25 
years to 3.5% in persons aged 50 years or older (P < 0.0001). There were significant 
differences in history of tuberculosis disease by geographic region, with the highest rate 
(3.8%) found in Nyanza (P = 0.0002), but there was no association between a self-reported 
history of tuberculosis and level of education, wealth index, or residence.
Overall, 96.2% of persons reporting prior tuberculosis also reported receiving treatment for 
it, and of those who received treatment, 81.4% reported completing it (Table 2). Receipt of 
tuberculosis treatment was significantly higher in persons with laboratory-diagnosed HIV 
infection (P < 0.0001) but not self-reported HIV infection. Among those treated, completion 
rates were significantly higher in those self-reporting HIV-positive status than those self-
reporting HIV-negative status (93.5% vs. 79.3%, P = 0.02) or laboratory-diagnosed as HIV-
positive compared to a laboratory-diagnosed as HIV-negative (92.0% vs. 73.5%, P = 0.02) 
(Table 2).
Among persons with laboratory-diagnosed and self-reported HIV infection, respectively, 
11.6% (95% CI: 8.9 to 14.3) and 21.0% (95% CI: 16.1 to 25.8) reported ever having had 
tuberculosis (Table 2) compared with 1.4% (95% CI: 1.1 to 1.7) and 1.7% (95% CI: 1.4 to 
2.0), respectively, of persons diagnosed or self-reported as HIV-negative. The respective 
HIV prevalence levels of laboratory-diagnosed and self-reported HIV infection in persons 
with prior tuberculosis were 33.2% (95% CI: 26.2 to 40.2) and 33.4% (95% CI: 26.7 to 
40.1) compared with 5.1% (95% CI: 4.5 to 5.8) and 3.2% (95% CI: 2.6 to 3.8), respectively, 
in those without prior tuberculosis (data not shown). Highly significant associations between 
HIV infection, laboratory-diagnosed or self-reported, and a history of prior tuberculosis 
were observed [for laboratory-diagnosed HIV infection: OR = 9.2; 95% CI: 6.6 to 12.8 
(Table 3) and for self-reported HIV infection: OR = 15.4; 95% CI: 10.8 to 21.9] (Table 4).
Factors Associated With HIV Co-infection in Persons With History of Tuberculosis
Compared with HIV-uninfected persons with prior tuberculosis, those co-infected with HIV 
and tuberculosis were more likely to be women (OR = 2.1; 95% CI: 1.1 to 3.9) (Table 5). 
HIV-infected persons with prior tuberculosis were more likely to be urban residents than 
HIV-uninfected persons with such a history (OR = 2.4; 95% CI: 1.2 to 4.5) and were more 
likely to be from Nyanza region (compared to Nairobi region; OR = 3.1; 95% CI: 1.1 to 8.5). 
HIV co-infected persons were wealthier than HIV-uninfected persons with prior tuberculosis 
(P = 0.006).
The proportion of HIV-uninfected persons with history of tuberculosis peaked among 
persons aged 25–34 years, at 27.4%. In contrast, the proportion of HIV-infected persons 
with a history of tuberculosis peaked higher and later among persons aged 35–44 years 
(34.1%) and 45–54 years (33.8%). The latter distribution corresponded with the age 
distribution for HIV prevalence in the population, where HIV prevalence peaked among 
persons aged 35–54 years, at 9.4% (Fig. 1).
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Awareness of HIV Serostatus and Access to HIV Care and ART
Overall, 47% of persons with HIV infection were aware of their infection.11 However, 
knowledge of HIV infection was significantly higher among persons with prior tuberculosis 
(77.2%) compared with persons without prior tuberculosis (42.9%) (Table 6). Among 
persons who were aware of their HIV infection, those with prior tuberculosis were more 
likely to be in HIV care (99.0%) than those without prior tuberculosis (89.8%) (P < 0.0001).
Among all HIV-infected persons, the proportion of those with and without prior tuberculosis 
who were on ART were 73.9% and 26.2%, respectively. Persons with prior tuberculosis 
therefore accounted for 28.8% (56/200) of all those taking ART. For persons who were 
aware of their HIV status, the respective proportions taking ART were 95.7% for those with 
prior tuberculosis and 61.2% for those without prior tuberculosis (P < 0.0001).
To estimate ART coverage for HIV-infected persons without prior tuberculosis who were in 
care, we examined persons with CD4 counts available and considered all persons on ART as 
treatment eligible, as well as those untreated who had a CD4 cell count ≤350 cells per 
microliter. The proportion of treatment-eligible persons without prior tuberculosis who were 
in care and receiving ART was 88.6%.
For both groups, ART coverage was lower when was assessed among all HIV-infected 
persons eligible for treatment, including those without knowledge of HIV serostatus. Overall 
coverage was 86.9% for persons with prior tuberculosis and 58.3% for those without prior 
tuberculosis (P < 0.0001). Approximately, three-quarters of HIV-infected persons on ART 
had achieved virologic suppression (76.6% among persons with prior tuberculosis and 
74.5% among persons without prior tuberculosis).
DISCUSSION
KAIS 2012 gives insight into the epidemics of HIV and tuberculosis and their association in 
Kenya. Overall, 5.6% of adults and adolescents aged 15 to 64 years were infected with HIV 
in the survey,11 and 2% of those who had heard of tuberculosis reported ever having had 
tuberculosis. In 2011, the Kenya Ministry of Health’s Division of Leprosy, Tuberculosis and 
Lung Disease reported a total of 103,981 cases of tuberculosis nationally.7 In KAIS 2012, 
almost one third of persons who reported prior tuberculosis were infected with HIV 
compared with 5.1% of persons without prior tuberculosis. In addition, 11.6% of persons 
with laboratory-diagnosed HIV infection reported having had tuberculosis previously. In 
contrast, only 1.4% of HIV-negative persons reported prior tuberculosis, indicative of the 
greatly increased relative risk for this disease that HIV infection confers at a population 
level. The association between HIV and tuberculosis was even stronger for the smaller 
group of persons self-reporting as HIV-positive, of whom 1 of 5 reported prior tuberculosis.
Reflective of the distribution of HIV infection itself,6 persons with a history of HIV-
associated tuberculosis were more likely than those with HIV-negative tuberculosis to be 
female, older, and residents of urban settings and Nyanza region, where HIV prevalence is 
high. They also were slightly wealthier. Just over one-quarter of all HIV-infected persons 
taking ART had a history of prior tuberculosis, which for many was likely the indicator 
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disease leading to HIV diagnosis and care, including ART. Since tuberculosis frequently 
occurs relatively early in the natural history of HIV infection,2 tuberculosis services may be 
playing an analogous role to those for the prevention of mother-to-child transmission of 
HIV, which are a frequent entry point for HIV care among women.
Although awareness of tuberculosis in the general population in Kenya was high, less than 
half of study participants knew that tuberculosis was curable in persons living with HIV. 
The finding that HIV-infected people, especially those reporting their own HIV infection, 
had significantly higher levels of knowledge suggests that many may have acquired this 
understanding from their own disease experience. Nonetheless, as only about two-thirds to 
three-quarters of persons with HIV knew that HIV-associated tuberculosis was curable, 
education about tuberculosis should constitute an important element of HIV/AIDS treatment 
literacy.
KAIS 2012 provided insight into access to treatment and care for HIV and tuberculosis. 
More than 95% of participants with self-reported prior tuberculosis reported receiving anti-
tuberculosis therapy, and more than 80% of the latter reported completing it. HIV treatment 
programs would benefit from emulating tuberculosis programs’ approach to cohort analysis 
of outcomes for all persons diagnosed with HIV.12 Although the process would be more 
complex because of the need for lifelong ART, analogous treatment outcomes can be 
defined and viral load suppression (or lack of it) could replace cure (or failure) in 
tuberculosis treatment as an outcome measure of HIV therapy.
KAIS 2012 reinforced observations from KAIS 2007 concerning the importance of 
individuals knowing their HIV serostatus.6 Provided people were aware of their HIV 
infection, access to HIV care and uptake of ART for those eligible were high. For persons 
who reported that they were infected with HIV, all persons with prior tuberculosis and 
approximately 90% without prior tuberculosis were in HIV care, and a similar proportion of 
such persons who were eligible for treatment were receiving ART. However, taking into 
account undiagnosed HIV infection, only about three-quarters of all HIV-infected persons 
with prior tuberculosis were in care compared to about 40% of HIV-infected persons 
without prior tuberculosis. Taking ART eligibility into account for all HIV-infected persons, 
including those undiagnosed and not in care, ART coverage was higher at 87% for persons 
with and 56% for persons without prior tuberculosis. In the broader KAIS sample, ART 
coverage regardless of tuberculosis knowledge fell in between these 2 estimates, at 61%.13 
Among persons who accessed ART, more than 70% were virally suppressed. These 
estimates show progress over a few years but are lower than coverage estimates from 
programmatic data or modeling efforts and fall short of universal access.14
In this analysis, approximately half of persons living with HIV were unaware of their HIV 
infection and thus unable to access potentially life-saving services.14 HIV testing is the 
essential entry into HIV care and treatment,15 but our data suggest that for many people 
tuberculosis disease may have been the reason for HIV diagnosis. If ART is to prevent 
morbidity including tuberculosis, HIV testing and ART provision must occur before people 
develop immunodeficiency-associated disease.16,17 WHO issued new guidelines in 2013 
advocating ART for all HIV-infected persons with CD4 cell counts of 500 cells per 
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microliter or below. Considerable prevention and therapeutic benefit occur at the population 
level with scale-up of ART initiated at the lower CD4 cell count thresholds still applied in 
most countries.18,19 Whatever future policy decisions are made,4 the critical requirements 
are widespread HIV testing, greatly increased knowledge of HIV serostatus, and timely 
implementation of ART, especially for those most immunosuppressed.
There were several limitations to the present study. History of tuberculosis was self-
reported, and different clinical categories, such as new cases, recurrences, treatment failures, 
and drug-resistant cases, could not be explored. Self-reports of HIV infection were not 
necessarily accurate, and recall bias could have influenced participants’ reporting of 
previously received testing, treatment and care services, and results. Despite its public health 
importance, tuberculosis is still a relatively rare event and numbers were small for further 
analyses. Cross-sectional surveys like KAIS 2012 have intrinsic biases because participants 
likely differ from nonparticipants who may have been excluded because of factors relevant 
to both HIV infection and tuberculosis, including through hospitalization or death, resulting 
in potential under-estimation of the true burden of tuberculosis and HIV in the population. 
North Eastern region, the region of the country with the lowest HIV prevalence and a 
relatively small population, was excluded for reasons of insecurity, so the study was not 
perfectly representative of the whole country. Despite these and other limitations, this 
national survey has given a unique assessment of the tuberculosis and HIV situation in 
Kenya not available through routine surveillance or program evaluations.
Despite substantial progress since KAIS 2007,6 KAIS 2012 highlights important areas for 
improvement. Without universal knowledge of HIV serostatus in this country with a 
generalized HIV epidemic, the full benefit of ART for prevention of HIV transmission as 
well as of morbidity and death, including from tuberculosis, will not be realized.20,21 Much 
greater emphasis on preventing tuberculosis among persons living with HIV is required.
National surveys of tuberculosis itself, for assessment of prevalence, evaluation of case 
finding, and tracking of anti-tuberculous drug resistance, must also be supported in high 
burden countries, such as Kenya. The inclusion of tuberculosis-specific data in KAIS 2012 
should lead to increased understanding, enhanced commitment to policy setting and 
planning for both HIV and tuberculosis, and improved services for both diseases, which 
remain among the most important health challenges in Kenya and on the African continent.
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TABLE 1
Knowledge About Tuberculosis Among Persons Aged 15–64 Years by Demographic Characteristics and HIV 
Status, Kenya AIDS Indicator Survey 2012
All
Participants
Have You Ever Heard of an 
Illness
Called Tuberculosis?*
Can Tuberculosis be Cured?
†
Can Tuberculosis be Cured 
in
People With HIV?‡
Unweighted, N Unweighted, n
Weighted 
%
(95% CI) Unweighted, n
Weighted 
%





 Men 5745 5613 97.7 (97.3 to 
98.2)
4914 87.0 (85.6 to 
88.3)
2378 49.1 (47.0 to 
51.3)
 Women 7930 7605 95.9 (95.3 to 
96.6)
6459 84.3 (83.1 to 
85.6)
2816 44.3 (42.4 to 
46.1)
Age category, yrs
 15–24 4528 4344 95.9 (95.2 to 
96.6)
3494 79.3 (77.4 to 
81.2)
1428 41.6 (39.4 to 
43.7)
 25–29 2138 2081 97.6 (96.8 to 
98.4)
1808 86.5 (84.7 to 
88.4)
802 44.6 (41.8 to 
47.5)
 30–39 3099 3013 97.1 (96.4 to 
97.9)
2707 89.3 (87.9 to 
90.6)
1330 50.5 (48.0 to 
52.9)
 40–49 2003 1934 96.8 (95.9 to 
97.7)
1721 89.2 (87.5 to 
90.8)
879 51.3 (48.2 to 
54.4)
 50–64 1907 1846 96.7 (95.8 to 
97.6)
1643 88.4 (86.6 to 
90.2)




 No primary 1560 1443 91.1 (88.6 to 
93.6)
1208 81.8 (78.4 to 
85.1)




1156 1114 95.8 (94.3 to 
97.4)
915 80.1 (76.8 to 
83.4)




4303 4203 97.7 (97.1 to 
98.2)
3613 85.2 (83.8 to 
86.7)




6648 6450 97.0 (96.5 to 
97.6)
5630 86.8 (85.5 to 
88.1)
2845 49.8 (47.9 to 
51.8)
Region
 Nairobi 1731 1701 98.4 (97.5 to 
99.2)
1542 90.9 (89.2 to 
92.6)
859 56.4 (52.9 to 
59.9)
 Central 1578 1547 98.1 (97.4 to 
98.8)
1364 89.3 (87.1 to 
91.4)
571 41.4 (37.7 to 
45.0)
 Nyanza 1829 1760 96.4 (95.0 to 
97.7)
1500 85.6 (83.4 to 
87.9)




1258 1203 95.6 (93.8 to 
97.4)
1044 86.1 (83.0 to 
89.2)




1220 1167 95.5 (94.1 to 
96.9)
961 82.5 (78.0 to 
87.0)
398 40.6 (35.7 to 
45.4)
 Eastern North 1217 1166 95.9 (93.7 to 
98.1)
1056 91.6 (87.4 to 
95.7)
343 33.3 (27.0 to 
39.6)
 Eastern South 1460 1413 96.9 (96.0 to 
97.8)
1168 82.9 (79.8 to 
86.1)
405 35.7 (32.5 to 
39.0)
 Western 1675 1604 95.6 (94.5 to 
96.8)
1226 75.9 (73.0 to 
78.7)
546 44.5 (41.5 to 
47.4)
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All
Participants
Have You Ever Heard of an 
Illness
Called Tuberculosis?*
Can Tuberculosis be Cured?
†
Can Tuberculosis be Cured 
in
People With HIV?‡
Unweighted, N Unweighted, n
Weighted 
%
(95% CI) Unweighted, n
Weighted 
%




 Coast 1707 1657 97.4 (96.1 to 
98.6)
1512 90.8 (88.7 to 
92.9)
703 48.7 (44.7 to 
52.8)
Residence
 Rural 8614 8252 95.9 (95.3 to 
96.5)
6909 83.1 (81.7 to 
84.6)
2910 43.7 (41.6 to 
45.8)
 Urban 5061 4966 98.0 (97.5 to 
98.6)
4464 89.3 (87.9 to 
90.8)
2284 50.5 (48.2 to 
52.9)
Wealth index
 Poorest 2839 2688 95.0 (93.7 to 
96.2)
2239 83.0 (80.5 to 
85.4)
901 43.4 (39.2 to 
47.5)
 Second 2849 2730 95.7 (94.8 to 
96.7)
2266 81.8 (79.9 to 
83.8)
955 42.9 (39.9 to 
45.9)
 Middle 2660 2566 96.3 (95.4 to 
97.3)
2150 82.6 (80.8 to 
84.4)
955 45.4 (42.7 to 
48.0)
 Fourth 2564 2511 97.9 (97.1 to 
98.6)
2221 87.8 (86.1 to 
89.5)
1027 45.6 (42.9 to 
48.3)
 Richest 2745 2705 98.4 (97.9 to 
99.0)
2480 91.5 (90.0 to 
93.1)




 HIV+ 363 353 97.3 (95.5 to 
99.0)
334 94.6 (92.2 to 
97.0)
265 78.4 (72.1 to 
84.7)
 HIV− 9214 8956 97.3 (96.9 to 
97.8)
7817 86.7 (85.7 to 
87.8)
3692 48.6 (47.0 to 
50.3)
 Never tested/
  never received
  results
4098 3909 95.7 (95.0 to 
96.5)
3222 82.4 (80.6 to 
84.2)




 HIV+ 648 635 97.8 (96.5 to 
99.1)
573 89.4 (86.6 to 
92.3)
385 67.7 (63.2 to 
72.2)
 HIV− 10,951 10,584 96.6 (96.2 to 
97.1)
9095 85.2 (84.0 to 
86.4)
3996 44.7 (43.1 to 
46.4)




Among participants who said they have ever heard about tuberculosis.
‡
Among participants who said that tuberculosis can be cured.
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TABLE 2
History and Treatment of Tuberculosis Among Persons Aged 15–64 Years Who Had Ever Heard of 






Tuberculosis Ever Had Tuberculosis*
Ever Been Treated for the
Tuberculosis† Completed TB Treatment‡
Unweighted, N Unweighted, n
Weighted 
%
(95% CI) Unweighted, n
Weighted 
%




Total 13,195 271 2.0 (1.7 to 
2.2)
261 96.2 (93.7 
to 98.8)
168 81.4 (75.0 
to 87.9)
Sex
 Men 5604 139 2.4 (2.0 to 
2.8)
133 95.4 (91.7 
to 99.1)
84 78.9 (70.0 
to 87.7)
 Women 7591 132 1.6 (1.3 to 
2.0)
128 97.1 (93.8 
to 100)
84 84.4 (76.2 
to 92.6)
Age category, yrs
 15–24 4335 27 0.6 (0.3 to 
0.8)
25 87.8 (71.7 
to 100)
14 62.7 (39.1 
to 86.3)
 25–29 2079 29 1.4 (0.8 to 
1.9)
26 90.1 (79.3 
to 100)
20 89.2 (77.1 
to 100)
 30–39 3011 81 2.7 (2.0 to 
3.4)
79 97.3 (93.5 
to 100)
51 81.7 (70.8 
to 92.6)
 40–49 1928 67 3.1 (2.2 to 
4.0)
66 99.8 (99.5 
to 100)
45 89.0 (77.1 
to 100)
 50–64 1842 67 3.5 (2.6 to 
4.4)
65 97.6 (94.3 
to 100)




 No primary 1436 34 1.8 (1.0 to 
2.6)
33 99.4 (98.3 
to 100)
16 79.0 (53.9 
to 100)
 Incomplete primary 1113 21 2.2 (1.3 to 
3.2)
20 91.9 (76.6 
to 100)
12 70.9 (46.5 
to 95.2)
 Complete primary 4193 74 1.7 (1.3 to 
2.1)
69 92.5 (85.9 
to 99.1)
44 76.1 (63.8 
to 88.5)
 Secondary or higher 6445 142 2.1 (1.7 to 
2.5)
139 98.4 (96.4 
to 100)
96 85.7 (78.9 
to 92.6)
Region
 Nairobi 1700 35 2.2 (1.5 to 
2.9)
35 100 24 83.6 (65.6 
to 100)
 Central 1544 32 1.9 (1.3 to 
2.6)
30 92.8 (82.6 
to 100)
21 82.5 (65.3 
to 99.8)
 Nyanza 1756 66 3.8 (2.7 to 
4.8)
63 95.8 (91.1 
to 100)
43 87.1 (75.3 
to 98.8)
 Rift Valley North 1201 16 1.4 (0.7 to 
2.0)
15 91.8 (76.7 
to 100)
11 83.4 (60.1 
to 100)
 Rift Valley South 1167 18 1.6 (0.6 to 
2.5)
18 100 10 71.9 (50.7 
to 93.0)
 Eastern North 1165 32 2.9 (1.8 to 
4.0)
31 97.7 (93.2 
to 100)
18 89.0 (74.3 
to 100)



















Tuberculosis Ever Had Tuberculosis*
Ever Been Treated for the
Tuberculosis† Completed TB Treatment‡
Unweighted, N Unweighted, n
Weighted 
%
(95% CI) Unweighted, n
Weighted 
%




 Eastern South 1410 21 1.4 (0.8 to 
2.1)
21 100 13 83.4 (61.6 
to 100)
 Western 1603 25 1.6 (0.9 to 
2.3)
23 93.1 (83.5 
to 100)
10 62.8 (34.1 
to 91.5)
 Coast 1649 26 1.5 (0.9 to 
2.0)
25 95.0 (85.0 
to 100)
18 86.5 (69.2 
to 100)
Residence
 Rural 8238 167 2.0 (1.6 to 
2.4)
160 95.9 (92.5 
to 99.2)
98 80.6 (72.5 
to 88.7)
 Urban 4957 104 1.9 (1.5 to 
2.3)
101 96.9 (93.2 
to 100)
70 82.8 (72.3 
to 93.3)
Wealth index
 Poorest 2683 61 2.1 (1.3 to 
2.8)
60 99.8 (99.5 
to 100)
33 77.3 (65.4 
to 89.3)
 Second 2722 61 2.1 (1.5 to 
2.8)
59 95.6 (89.4 
to 100)
37 77.5 (64.1 
to 90.8)
 Middle 2562 40 1.7 (1.0 to 
2.3)
37 93.4 (86.0 
to 100)
26 85.9 (72.0 
to 99.7)
 Fourth 2506 65 2.4 (1.8 to 
3.0)
62 94.4 (88.2 
to 100)
43 87.0 (76.0 
to 98.1)
 Richest 2704 44 1.6 (1.0 to 
2.1)
43 98.2 (94.6 
to 100)
29 80.3 (63.1 
to 97.5)
Reported HIV status
 HIV+ 352 74 21.0 (16.1 
to 25.8)
73 99.0 (96.9 
to 100)
56 93.5 (86.1 
to 100)
 HIV− 8946 155 1.7 (1.4 to 
2.0)
148 95.3 (91.4 
to 99.1)
94 79.3 (70.9 
to 87.7)
 Never tested/never
  received results
3897 42 1.0 (0.7 to 
1.4)
40 94.0 (85.9 
to 100)
18 62.3 (40.6 
to 84.1)
Laboratory HIV result
 HIV+ 633 75 11.6 (8.9 to 
14.3)
75 100 59 92.0 (83.8 
to 100)
 HIV− 10,570 159 1.4 (1.1 to 
1.7)
150 94.2 (90.1 
to 98.3)
86 73.5 (64.6 
to 82.5)
Totals may vary between variables due to missing data.
*
Among all patients who have ever heard of tuberculosis.
†
Among patients who said they have ever had been told by a doctor that they had tuberculosis.
‡
Among patients who said that they had been treated for tuberculosis and were not currently on treatment.
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TABLE 3
Association Between History of Tuberculosis and Laboratory-Diagnosed HIV Status Among Persons Aged 





HIV+ 75 558 633
HIV− 159 10,411 10,570
Total 234 10,969 11,203
OR = 9.2 (95% CI: 6.6 to 12.8).













Mbithi et al. Page 18
TABLE 4
Association Between History of Tuberculosis and Self-Reported HIV Status Among Persons Aged 15–64 
Years Who Had Ever Heard of Tuberculosis, Kenya AIDS Indicator Survey 2012
History of Tuberculosis No History of Tuberculosis Total
HIV+ 74 278 352
HIV− 155 8791 8966
Total 229 9089 9318
OR = 15.4 (95% CI: 10.8 to 21.9).
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TABLE 5
History of Tuberculosis by Laboratory-Diagnosed HIV Status and Associations With Demographic 
Characteristics and Self-Reported HIV Status Among Persons Aged 15–64 Years Who Had Ever Heard of 












(95% CI) OR (95% CI) P
Sex
 Men 30 46.0 (34.9 to 
57.2)
88 64.4 (55.5 to 
73.2)
1.0 —
 Women 45 54.0 (42.8 to 
65.1)
71 35.6 (26.8 to 
44.5)
2.1 (1.1 to 3.9) 0.0173
Age category, yrs
 15–24 0 — 27 17.6 (11.0 to 
24.1)
— <0.0001
 25–29 5 5.5 (0 to 11.2) 17 12.1 (5.7 to 
18.4)
1.0 —
 30–39 29 38.5 (26.8 to 
50.2)
43 28.8 (20.2 to 
37.5)
3.0 (0.9 to 10.0) 0.0721
 40–49 18 23.6 (13.8 to 
33.4)
33 19.2 (12.0 to 
26.4)
2.9 (0.8 to 10.5) 0.1019
 50–64 23 32.4 (19.8 to 
45.0)
39 22.4 (14.9 to 
29.8)
3.3 (1.0 to 11.4) 0.0577
Highest educational attainment
 No primary 4 3.0 (0 to 6.1) 24 5.3 (2.2 to 8.4) 1.0 —
 Incomplete primary 3 5.4 (0 to 11.7) 15 10.3 (5.0 to 
15.5)
1.1 (0.2 to 7.1) 0.9168
 Complete primary 18 24.1 (12.7 to 
35.5)
46 30.0 (22.3 to 
37.6)
1.6 (0.4 to 6.3) 0.5361
 Secondary or higher 50 67.6 (55.4 to 
79.8)
74 54.4 (45.6 to 
63.2)
2.4 (0.7 to 8.5) 0.1695
Region
 Nairobi 7 8.9 (3.0 to 14.8) 19 11.8 (8.0 to 
15.5)
1.0 —
 Central 9 10.7 (4.3 to 
17.1)
21 15.4 (10.9 to 
19.9)
1.0 (0.3 to 3.5) 0.9787
 Nyanza 32 44.6 (32.9 to 
56.3)
26 18.6 (12.8 to 
24.5)
3.1 (1.1 to 8.5) 0.0282
 Rift Valley North 4 5.5 (0.2 to 10.9) 8 7.9 (4.7 to 11.0) 0.9 (0.2 to 4.4) 0.9234
 Rift Valley South 7 12.6 (4.0 to 
21.1)
11 13.3 (5.2 to 
21.4)
1.2 (0.3 to 5.6) 0.8248
 Eastern North 4 0.7 (0 to 1.3) 25 2.2 (1.6 to 2.8) 0.4 (0.1 to 1.6) 0.1933
 Eastern South 3 7.3 (0 to 14.9) 15 12.6 (8.7 to 
16.6)
0.7 (0.1 to 3.7) 0.7094
 Western 3 4.5 (0 to 9.0) 19 11.1 (8.5 to 
13.8)
0.6 (0.1 to 2.5) 0.4907
 Coast 6 5.3 (1.3 to 9.3) 15 7.1 (4.8 to 9.4) 1.0 (0.3 to 3.9) 0.9920
Residence

























(95% CI) OR (95% CI) P
 Rural 38 51.2 (39.4 to 
63.0)
109 70.6 (64.2 to 
77.0)
1.0 —
 Urban 37 48.8 (37.0 to 
60.6)
50 29.4 (23.0 to 
35.8)
2.4 (1.2 to 4.5) 0.0100
Wealth index
 Poorest 10 13.6 (5.3 to 
21.9)
44 24.0 (14.1 to 
33.8)
1.0 —
 Second 11 15.6 (6.0 to 
25.2)
41 25.5 (17.2 to 
33.8)
1.2 (0.4 to 3.4) 0.7421
 Middle 17 26.6 (13.4 to 
39.8)
17 12.2 (6.2 to 
18.2)
4.3 (1.5 to 11.9) 0.0055
 Fourth 23 25.1 (15.0 to 
35.3)
35 23.6 (15.4 to 
31.7)
2.3 (0.8 to 6.5) 0.1065
 Richest 14 19.0 (9.0 to 
29.1)
22 14.8 (8.3 to 
21.3)
2.5 (0.8 to 7.5) 0.1088
Reported HIV status
 HIV+ 57 77.2 (66.4 to 
88.0)
6 3.8 (0.6 to 7.0) 97.8 (33.9 to 
282.0)
<0.0001
 HIV− 12 16.2 (7.4 to 
25.0)
124 76.4 (68.8 to 
84.0)
1.0 —
 Never tested/never received 
results
5 6.6 (0 to 14.4) 29 19.8 (12.7 to 
26.8)
2.0 (0.6 to 6.6) 0.2660
Totals may vary between variables due to missing data. Due to rounding errors, the sum of stratum-specific estimates may not equal 100%.
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TABLE 6
Awareness of HIV-Positive Status and HIV Treatment Characteristics Among Laboratory-Diagnosed HIV-




(95% CI) Unweighted, n
Weighted %
(95% CI) P
Knowledge of HIV+ status <0.0001
 Aware of HIV+ 59 77.2 (66.8 to 87.6) 238 42.9 (36.9 to 48.8)
 Not aware 16 22.8 (12.4 to 33.2) 320 57.1 (51.2 to 63.1)
 Total 75 538
Care and treatment among those aware of HIV+ 
status
<0.0001
 Aware of HIV+, in care and on ART 56 95.7 (92.0 to 99.4) 144 61.2 (54.8 to 67.6)
 Aware of HIV+, in care and not on ART 3 4.3 (0.6 to 8.0) 71 28.6 (22.5 to 34.7)
 Aware of HIV+, not in care and not on ART 0 — 23 10.2 (6.6 to 13.8)
 Total 59 238
Care and treatment among all persons HIV+ <0.0001
 Aware of HIV+, in care and on ART 56 73.9 (63.4 to 84.3) 144 26.2 (21.3 to 31.1)
 Aware of HIV+, in care and not on ART 3 3.3 (0.5 to 6.2) 71 12.3 (9.0 to 15.5)
 Aware of HIV+, not in care and not on ART 0 — 23 4.4 (2.8 to 6.0)
 Not aware of HIV+ 16 22.8 (12.4 to 33.2) 320 57.1 (51.2 to 63.1)
 Total 75 558
Coverage of ART among persons aware of HIV+, 
in
 care, and eligible for ART*
<0.0001
 In care and on ART 29 100† 80 88.6 (81.6 to 95.7)
 In care and not on ART 0 — 8 11.4 (4.3 to 18.4)
 Total 29 88




 In care and on ART 29 86.9 (74.2 to 99.5)† 80 58.3 (47.6 to 69.0)
 In care and not on ART 0 — 8 7.5 (2.8 to 12.2)
 Not aware of HIV+ 4 13.1 (0.5 to 25.8)† 46 34.2 (24.4 to 43.9)
 Total 33 134
Viral load 0.7177
 Aware of HIV+, on ART, suppressed‡ 43 76.6 (67.3 to 85.8) 103 74.5 (68.0 to 81.0)
 Aware of HIV+, on ART, not suppressed 13 23.4 (14.2 to 32.7) 36 25.5 (19.0 to 32.0)
 Total 56 139
*
Eligibility for ART defined as CD4 ≤350 cells per microliter, prior history of tuberculosis, and ever taking ART.
†
Estimates based on sample sizes of <50 observations and may be unreliable.
‡
HIV RNA concentration <1000 copies per milliliter.
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